title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Acknowledgements | This study was supported by Chang Gung Memorial Hospital (CMRPD1M0042, BMRP553), Healthy Aging Research Center, Chang Gung University from the Featured Areas Research Center Program within the Framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (EMRPD1M0411), National Science a... | PMC10558527 | ||
Author contributions | Y.W.C. performed the main statistical analysis, interpreted the data and wrote the first draft of the manuscript. K.Y.L. contributed to development of intervention protocol and data analysis. P.H.H. contributed to project management, data collection and preliminary data analysis. C.H.L. and H.T.L. assisted in data coll... | PMC10558527 | ||
Data availability | The datasets used and/or analyzed during the current study are not publicly available due to the confidentiality issue but are available from the corresponding author upon reasonable request. | PMC10558527 | ||
Competing interests | The authors declare no competing interests. | PMC10558527 | ||
References | PMC10558527 | |||
Background: | PRESSURE INJURY | 3M microfoam™ surgical tape (3ST: 3M Japan Limited) is used for pressure wound control of medical equipment. It is cushioned and can be fitted to any body part. Here we investigated whether 3ST prevents nasal pressure injury associated with nasotracheal intubation (NTI). | PMC9839254 | |
Methods: | We conducted a prospective, randomized double-blind study, enrolling 63 patients aged 20 to 70 years, who underwent general anesthesia with NTI. They were divided into 2 groups; those treated with 3ST (group | PMC9839254 | ||
Results: | PRESSURE INJURY | Nasal pressure injury was observed in 7 and 19 patients from groups | PMC9839254 | |
Conclusion: | PRESSURE INJURY | 3ST prevents nasal pressure injury associated with NTI. | PMC9839254 | |
1. Introduction | NASAL BLEEDING, PRESSURE ULCER, PRESSURE INJURY, PRESSURE INJURY, COMPLICATIONS | Nasotracheal intubation (NTI) is frequently necessary during dental and oral maxillofacial surgeries, specifically during operations with operative field and airway converge. However, some complications associated with NTI such as nasal bleeding,The National Pressure Ulcer Advisory Panel, European Pressure Ulcer Adviso... | PMC9839254 | |
2. Materials and methods | PMC9839254 | |||
2.1. Ethics approval and consent to participate | This study was conducted in accordance with the ethical standards of the Declaration of Helsinki (1964) and its subsequent amendments. Moreover, this study adhered to the Consolidated Standards of Reporting Trials guidelines (CONSORT) and was approved by the Ethics Committee at the School of Dentistry, Aichi Gakuin Uni... | PMC9839254 | ||
2.2. Study design and population | skin irritation | CONSTRICTION, RECRUITMENT | We conducted a prospective, randomized double-blind study with a blinded evaluator and patients, enrolling 63 patients aged 20 to 70 years and scheduled to undergo general anesthesia with NTI for oral and maxillofacial surgery. Exclusion criteria were those withan obvious nostril constriction (n = 0) and deformities in... | PMC9839254 |
2.3. Anesthesia and intubation methods | The same method of anesthesia was employed for all patients. The standard vital signs monitors (electrocardiogram, blood pressure, and oxygen saturation) were inspected. Anesthesia was induced using propofol (3 Protection method of nasal wing. Group | PMC9839254 | ||
2.4. Measurements | PRESSURE ULCER, PRESSURE INJURY | The primary outcome was the presence or absence of nasal pressure injury observed from the nasal tip to the nasal alar. After extubation, an assessment was performed by the operating room nurse, who was not informed whether the patient belonged to group Furthermore, we compared the price of 3ST used in this study and t... | PMC9839254 | |
2.5. Statistical analysis | We estimated that a minimum sample of 56 patients would be needed, where the threshold response, Since the use of statistical tests in the absence of reliable sample size calculation decreases its weightage, we calculated our final sample size considering an expected dropout rate of 0.05 based on our pilot study. Hence... | PMC9839254 | ||
3. Results | PMC9839254 | |||
3.1. Patients’ background | Sixty-three patients were selected to participate in this study from September 2021 to November 2021. The participant CONSORT flow diagram is presented in Figure Patient demographic information.Values are in numbers or median (quartiles 1–3). | PMC9839254 | ||
3.2. Presence or absence of nasal pressure injury | PRESSURE INJURY | As depicted in Table Distribution of the patients based on nasal pressure injury associated with nasotracheal intubation.Values are in numbers. | PMC9839254 | |
3.3. Comparison of the price of the surgical tape and hydrocolloid formulation | Table Comparison of the surgical tape prices and hydrocolloid formulation (1 USD = 115 yen). | PMC9839254 | ||
4. Discussion and conclusion | ischemia | ISCHEMIA, PRESSURE INJURY | In this study, on using 3ST for preventing nasal pressure injury associated with NTI, we observed a significant difference in the frequency of nasal pressure injury from the nasal tip to the nasal alar between the groups. Generally, nasal pressure injury during NTI is caused by local ischemia between the nasal columell... | PMC9839254 |
Acknowledgements | The authors would like to thank Enago ( | PMC9839254 | ||
Abbreviations: | Hashimoto | HASHIMOTO, PRESSURE INJURY | 3m microfoam™ surgical tapenasotracheal intubationThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.Trial Registration: UMIN-CTR (Registration No. UMIN000045524, date of first registration: 21/09/2021).This study was conducted in acc... | PMC9839254 |
References | PMC9839254 | |||
Abstract | These authors contribute equally to this work. | PMC10798291 | ||
Background | pruritus, postoperative nausea and vomiting | Butorphanol has been used to reduce the incidence and severity of neuraxial morphine-induced pruritus. Palonosetron is a commonly used antiemetic for the prevention of postoperative nausea and vomiting. The aim of our study was to compare the effective dose in 50% of subjects (ED50) of intravenous butorphanol infusion ... | PMC10798291 | |
Methods | pruritus, NRS | GROUP B | A total of 120 parturients were randomly assigned to receive an intravenous bolus injection of palonosetron plus continuous infusion of butorphanol (Group P + B) or an intravenous bolus of saline plus continuous infusion of butorphanol (Group B) after epidural administration of morphine. The antipruritic effect was gra... | PMC10798291 |
Results | pruritus | GROUP B | The ED50 (mean [95% confidence interval (CI)]) of the dose of intravenous butorphanol infusion for preventing moderate to severe pruritus was lower in Group P + B (3.29 µg/kg/min [3.25–3.34 µg/kg/min]) than in Group B (3.57 µg/kg/min [3.47–3.67 µg/kg/min]) ( | PMC10798291 |
Conclusions | Under the conditions of the present study, a prophylactic use of 0.25 mg palonosetron reduced the ED50 of prophylactic infusion of butorphanol by approximately 8% to achieve a satisfactory antipruritic effect after epidural morphine for post-caesarean analgesia. | PMC10798291 | ||
Keywords | PMC10798291 | |||
Introduction | Neuraxial administration of morphine, a hydrophilic μ-opioid receptor agonist with well-established effectiveness and a long duration of action, is one of the most effective methods for post-caesarean analgesia [ | PMC10798291 | ||
Materials and methods | PMC10798291 | |||
Design and study subjects | This prospective, double-blinded, randomized dose–response clinical trial was approved by the Research Ethics Committee of Women’s Hospital, School of Medicine, Zhejiang University (Number: IRB-20210132-R). Written informed consent was obtained from all parturients. The trial was registered at the Chinese Clinical Tria... | PMC10798291 | ||
Study protocol | Bradycardia, nausea, ’, Postoperative pain, pain, pruritus, NRS pain, hypotension, Hypotension, height of sensory block | HYPERTENSION, GROUP B | Based on a computer-generated random number sheet, patients were randomly allocated into Group B (intravenous administration of normal saline plus continuous intravenous pump of butorphanol) or Group P + B (intravenous administration of palonosetron plus continuous intravenous pump of butorphanol). An investigator (Hui... | PMC10798291 |
Statistical analysis | The sample size of the current study was based on the method of up-down allocation [To estimate ED50 and its confidence interval and compare the ED50 value between the two groups, we used RStudio (version 4.2.1) with the package of ed50simulation (version:0.1.1) based on the method described by Dixon-Mood [ | PMC10798291 | ||
Discussion | nausea, nausea and dizziness, vomiting, constipation, dizziness, pruritus, neuraxial morphine-induced, nausea,, urinary retention | ADVERSE REACTIONS | This prospective, double-blinded, randomized dose–response trial is the first study focusing on the infusion dose of butorphanol for preventing morphine-induced pruritus in women having elective caesarean delivery. Our results showed that prophylactic administration of 0.25 mg palonosetron significantly decreases the r... | PMC10798291 |
Conclusions | In summary, under the conditions of this study, prophylactic use of 0.25 mg palonosetron reduced the ED50 of butorphanol infusion by approximately 8% to achieve a satisfactory antipruritic effect after epidural administration of morphine in healthy parturients. | PMC10798291 | ||
Ethics approval and informed consent | This randomised, double-blinded study was approved by the Ethical Committee of Women’s Hospital, Zhejiang University School of Medicine (Hangzhou, China) (Approval No. IRB-20210132-R), and was registered prior to patient enrolment at the Chinese Clinical Trials (Registration No. ChiCTR2200055313, | PMC10798291 | ||
Consent for publication | All authors have read and approved the manuscript, and agree to submit to the journal. | PMC10798291 | ||
Authors’ contributions | CCJ | Conceptualization: LHS, LJ; Data curation: LYW, QX; Formal analysis: HW; participants enrolling: CCJ; Drafting of manuscript: LHS, LJ; Revision of manuscript: XZC; Final approval: LHS, LJ, XZC. Funding acquisition: LHS, XZC. All authors agreed to be accountable for all aspects of the work. | PMC10798291 | |
Disclosure statement | No potential conflict of interest was reported by the author(s). | PMC10798291 | ||
Data availability statement | The data supporting the study findings are available from the corresponding author upon reasonable request. | PMC10798291 | ||
References | PMC10798291 | |||
Methods | SECONDARY | We randomly assigned healthy volunteers to undergo a determined skin cleansing protocol for total hip arthroplasty in the supine position to either a colored or colorless skin cleansing protocol. The adequacy of skin preparation was compared between orthopedic consultants and residents. The colorless disinfectant was m... | PMC9980739 | |
Results | Fifty-two healthy volunteers (104 legs; 52 colored and 52 colorless) underwent surgical skin preparation. The number of legs incompletely disinfected was significantly higher in colorless compared to colored disinfectant group (38.5% (n = 20) vs. 13.5% (n = 7); p = 0.007). Regardless of the disinfectant, consultants pe... | PMC9980739 | ||
Conclusions | hip arthroplasty | Application of colorless skin disinfectants for hip arthroplasty cleansing protocol led to decreased skin coverage among consultants and residents compared to colored preparations. Colored disinfectants remain the gold standard in hip surgery, however we should be aiming to develop newer colored disinfectants with long... | PMC9980739 | |
Data Availability | All relevant data are within the paper and its | PMC9980739 | ||
Introduction | SSI | SURGICAL SITE INFECTION | Surgical site infections (SSI) can occur from 30 days postoperatively to within 1 year post surgery, if implants are used [ | PMC9980739 |
Objectives | THA | SKIN | We conducted an experimental study comparing the skin coverage with a colored and a colorless preparation following a standardized protocol in simulated total hip arthroplasty (THA) cases. Skin disinfection for THA in the supine position can be challenging due to the large and complex surgical field with some skin area... | PMC9980739 |
Materials and methods | RECRUITMENT | We conducted this randomized controlled clinical, single-centre trial between March and September 2021 at the Hannover Medical School (MHH). No changes to the methods were made after trial start. The local ethical committee approved the study (Nr.: 9579_BO_S_2021), and written informed consent was obtained from all hea... | PMC9980739 | |
Participants | Volunteers were recruited during clinical contact and in the context of student teaching. The key inclusion criteria were healthy adults aged between 18 and 65 years old with a body mass index of under 30 kg/m | PMC9980739 | ||
Randomization and cleansing protocol | An orthopaedic resident or an orthopaedic consultant were randomly assigned in a 1:1 ratio. They were randomly asked to scrub the right or left leg of the volunteer and to start with a colored or colorless antiseptic, as shown in the chart ( | PMC9980739 | ||
Randomization and treatment regime used in our study. | A commercially available alcohol + PVP-I–based skin disinfectant (Braunoderm®, B. Braun, Melsungen, Germany) was used as a colored disinfectant, and Schülke-Optics (Schülke & Mayr, Norderstedt, Germany) was used as a colorless solution. Schülke-Optics contains among other ingredients IPA and is used for training and fo... | PMC9980739 | ||
The leg was divided into 17 zones as demonstrated on the two images to the left: 1) thigh ventral, 2) thigh lateral, 3) thigh dorsal, 4) thigh medial, 5) knee ventral, 6) knee lateral, 7) knee dorsal, 8) knee medial, 9) lower leg ventral, 10) lower leg lateral, 11) lower leg dorsal, 12) lower leg medial, 13) foot ventr... | STERILE | The two images on the right show the appearance of the skin preparation under the UV light.The cleansing procedure started ventral. The sequence was: 1) the ventral thigh, 2) the lateral thigh, 3) the dorsal thigh, and 4) the medial thigh. The same sequence was performed for the zones around the knee, lower leg and foo... | PMC9980739 | |
Outcomes | SECONDARY | The primary outcome of interest was the number of legs with an incomplete scrubbed area.An incomplete skin cleansing area was defined as any visibly not disinfected skin part regardless of size. The secondary outcome was the cumulative size of these areas measured in square centimeters. | PMC9980739 | |
Assessment | Following skin disinfection, a fixed sequence of photographs was performed for documentation purposes. These photographs were systematically reviewed by an independent investigator and missed skin areas were documented, lined out and the area was measured in square centimeters.For this we used the “CAD-KAS Bild-Vermess... | PMC9980739 | ||
Figure demonstrating the areas missed and marked out through the use of the CAD-KAS system. | PMC9980739 | |||
Statistical analysis | Continuous variables were checked for normal distribution using the Shapiro–Wilk test, and are presented as mean ± standard deviation (SD). Categorical variables were described as frequencies with percentages. The primary data analyses followed the intention-to-treat principle, in which data from all participants were ... | PMC9980739 | ||
Results | The members of the two study groups were all medical students. They were similar with respect to demographic characteristics such as: age, weight and height. The ratio of women to men was 1:1. The overall percentage of uncleansed skin areas was significantly higher in the colorless disinfectant group compared with the ... | PMC9980739 | ||
Graph combining the resident and consultant skin preparation completeness based on the number of legs found to have been disinfected fully. | When comparing the use of colored and colorless disinfectants between consultants there was no statistically significant difference. In 26 legs disinfected by consultants using colored antiseptics, only one leg was partially disinfected (3.8%). In 26 legs disinfected by consultants using colorless antiseptics, five leg... | PMC9980739 | ||
Comparison between consultant and resident THA skin preparation when using colored vs. colorless skin antiseptic. | When comparing the use of colored and colorless disinfectants between residents there was a statistically significant difference. In 26 legs disinfected by residents using colored antiseptics, six legs were disinfected partially (23.1%). In 26 legs disinfected by residents using colorless antiseptics, 15 legs were disi... | PMC9980739 | ||
Graph demonstrating the difference in surface area of inadequately prepared skin (Colored antiseptic v.s. colorless antiseptic). | Dividing this data by the level of seniority of surgeon (consultant vs. resident) showed that the area of uncleansed skin was significantly smaller when prepped by a consultant.The total amount of uncleansed skin in square centimeters by residents using colorless vs. colored skin disinfectant was 16.10±47.89 vs. 1.29±3... | PMC9980739 | ||
Outcome data. | PMC9980739 | |||
Discussion | THA | SKIN LAXITY, SITE INFECTION, BLIND | We hypothesized that the visualization of skin antiseptics is an important factor in orthopaedic joint surgery. Surgical skin preparation of a complete leg in THA is more challenging than for example abdominal/spinal surgery because the areas are much larger, three-dimensional and sometimes outside one’s own field of v... | PMC9980739 |
Conclusions | We conclude that colored disinfectants remain the gold standard for skin preparation in hip surgery. The aim should be to use available, clearly visible, colored, alcohol-based disinfectants that also have residual antibacterial effect (e.g., due to addition of CHX [ | PMC9980739 | ||
Supporting information | PMC9980739 | |||
CONSORT 2010 checklist of information to include when reporting a randomised trial*. | (PDF)Click here for additional data file.(XLSX)Click here for additional data file. | PMC9980739 | ||
References | PMC9980739 | |||
Objective: | knee arthroplasty, TKA | To evaluate the efficacy and safety of perioperative cryotherapy combined with intra-articular injection of tranexamic acid (TXA) in total knee arthroplasty (TKA) and explore a new strategy of enhanced recovery after TKA. | PMC10662860 | |
Methods: | blood loss, postoperative pain | BLOOD LOSS, GROUP B, COMPLICATIONS | We randomly divided 200 patients into 4 groups: normal saline (10 mL) by drainage (Group A, placebo); intra-articular injection of TXA (1 g, 10 mL, Group B); normal saline (10 mL) and continuous cryotherapy postoperatively (Group C) and intra-articular injection of TXA (1 g, 10 mL) and continuous cryotherapy postoperat... | PMC10662860 |
Results: | blood loss | BLOOD LOSS | There were statistically significant differences in postoperative drainage volume, total blood loss, hidden blood loss, and visual analogue scale at rest and walking on postoperative day 1 (POD1), POD2, POD3, ROM (POD3, 7, discharge, postoperative month), circumference variation (POD3, 7), p-LOS, Hospital for Special S... | PMC10662860 |
Conclusion: | blood loss, postoperative swelling, pain | BLOOD LOSS, COMPLICATIONS | Continuous cryotherapy combined with intra-articular injection of TXA provides short-term advantages in reducing blood loss, pain, postoperative swelling, p-LOS and increasing ROM and joint function in the early postoperative period after TKA without increasing any severe complications. | PMC10662860 |
1. Introduction | knee arthroplasty, end-stage knee osteoarthritis, blood loss, TKA | BLOOD LOSS, COLD | Total knee arthroplasty (TKA) is recognized as an excellent surgical procedure for patients with end-stage knee osteoarthritis.Intravenous tranexamic acid (TXA) has been shown that can significantly reduce blood loss in total hip and knee arthroplasty.There are several other strategies to reduce BLV during perioperativ... | PMC10662860 |
2. Materials and methods | heart disease, phlebitis, osteoarthritis, allergy, anemia, vascular lesion, DVT, systemic rheumatic diseases, coagulopathy, liver/kidney failure, diabetes | RHEUMATOID ARTHRITIS, PULMONARY EMBOLISM, RECRUITMENT, GROUP B, HEART DISEASE, PHLEBITIS, OSTEOARTHRITIS, ALLERGY, SYSTEMIC LUPUS ERYTHEMATOSUS, DVT, ANEMIA, COAGULOPATHY, COLD, ANKYLOSING SPONDYLITIS, DIABETES | This prospective, double-blind, randomized, controlled study was conducted from February 2017 to July 2022. Recruitment was approved by the institutional review board and registered at the Chinese Clinical Trial Registry (ChiCTR2300071161). All patients provided written informed consent before participation. Inclusion ... | PMC10662860 |
2.1. Patient demographics | knee arthroplasty, DVT | DVT | From February 2017 to July 2022, 240 patients scheduled to undergo primary unilateral TKA were screened for inclusion in the study. Twenty-eight patients did not meet the inclusion criteria, and twelve patients were lost to follow-up at the 3-month endpoint, leading to 200 participants (Fig. Demographic data of the pat... | PMC10662860 |
2.2. Postoperative management | pain | Ankle dorsal, plantar flexion, and quadriceps strength exercises began in the recovery bay. These 4 regions would receive rivaroxaban (10 mg) orally when the drainage was removed at the first 48 postoperative hours. Patients received standard supervised physiotherapy daily, including continuous passive motion, strength... | PMC10662860 | |
2.3. Outcome assessment | blood loss, SSI, cold injury, DVT | BLOOD LOSS, SURGICAL SITE INFECTION, PERIOPERATIVE COMPLICATION, INTRAOPERATIVE BLOOD LOSS, DVT | Intraoperative blood loss, postoperative drainage volume (PDV), VAS at rest and walking on postoperative day 1 (POD1), POD2, POD3, ROM (POD3, 7, discharge, postoperative month), circumference variation (POD3, 7), postoperative length of stay (p-LOS), function score (Hospital for Special Surgery [HSS], discharge) and dr... | PMC10662860 |
2.4. Statistical analysis | Statistical analyses were performed in SPSS version 24 (SPSS Inc., Chicago, IL). Data are presented as means ± standard deviation (continuous variables) or raw numbers (qualitative variables). One-way ANOVA and Tukey’s post hoc test were used to evaluate parametric data, while the Mann–Whitney | PMC10662860 | ||
3. Results | PMC10662860 | |||
3.1. Primary outcomes | PMC10662860 | |||
3.1.1. Blood loss volume. | blood loss, intraoperative blood loss | BLOOD LOSS, GROUP B, INTRAOPERATIVE BLOOD LOSS | The PDV, TBL, HBL in Groups B (453.60 ± 52.84; 949.06 ± 224.94; 307.60 ± 83.34), C (437.50 ± 54.38; 851.40 ± 104.71; 274.06 ± 56.12), and D (313.76 ± 60.3; 689.96 ± 100.40; 208.86 ± 67.89) were generally lower than those in Group A (636.60 ± 99.13; 1075.68 ± 212.59; 363.02 ± 93.98) (The comparison of blood loss among t... | PMC10662860 |
3.1.2. Pain. | pain | GROUP B | On POD1, 2 and 3, pain scores at rest were significantly lower for Group B (4.44 ± 0.58; 3.02 ± 0.71; 1.86 ± 0.67), C (3.32 ± 0.84; 1.82 ± 0.69; 0.96 ± 0.70), and D (3.28 ± 0.81; 1.74 ± 0.57; 0.80 ± 0.54) than for Group A (5.58 ± 0.61; 4.24 ± 0.70; 4.44 ± 0.58) (The comparison of VAS of pain at rest among the 4 groups ... | PMC10662860 |
3.1.3. Joint swelling. | Circumference variation on POD3 and 7 were significantly lower for Group C (2.82 ± 0.44; 1.44 ± 0.46) and D (2.70 ± 0.27; 1.49 ± 0.36) than for Group A (4.25 ± 0.42; 4.01 ± 0.30) and B (4.23 ± 0.40; 3.90 ± 0.40) (The clinical effect among the 4 groups.HSS = Hospital for Special Surgery, POD = postoperative day, P-LOS =... | PMC10662860 | ||
3.2. Secondary outcomes | PMC10662860 | |||
3.2.1. Range of motion. | ROM on POD3, 7, discharge and 1M were significantly greater for Group C (55.34 ± 6.35; 76.74 ± 8.47; 98.22 ± 6.95; 116.54 ± 4.54) and D (55.36 ± 3.98; 75.40 ± 6.42; 98.00 ± 5.36; 116.10 ± 4.73) than for Group A (49.40 ± 4.14; 66.50 ± 3.35; 88.18 ± 3.85; 109.14 ± 2.41) and B (50.84 ± 4.44; 67.82 ± 2.88; 89.08 ± 2.95; 10... | PMC10662860 | ||
3.2.2. Postoperative length of stay and knee function. | GROUP B | P-LOS were significantly less for Group B (12.08 ± 1.41), C (10.76 ± 1.17), and D (10.46 ± 1.53) than for Group A (12.90 ± 1.33) (HSS score at discharge were significantly higher for Group C (86.58 ± 4.70) and D (85.94 ± 3.86) than for Group A (79.98 ± 4.48) and B (80.40 ± 3.21) ( | PMC10662860 | |
3.2.3. Oxycodone consumption, coagulation function and complications. | postoperative coagulation, DVT | DEEP VENOUS THROMBOSIS, SURGICAL SITE INFECTION, COMPLICATION, COMPLICATIONS, DVT | There was no statistically significant difference in total number and dose of oxycodone for Group A (36/50; 730 mg), B (37/50; 580), C (33/50; 530) and D (34/50; 560) among the 4 groups (The postoperative coagulation and complications.APTT = activated partial thromboplastin time, DVT = deep venous thrombosis, PT = post... | PMC10662860 |
4. Discussion | swelling, blood loss, DVT, pain, TKA | BLOOD LOSS, COLD, COMPLICATIONS, DVT | Cryotherapy, also known as cold therapy, as an age-old treatment method on acute soft tissue injury, is gradually applied to TKA postoperative rehabilitation, which is also utilized to enhance recovery and outcomes after TKA.How to further reduce perioperative blood loss of TKA is the point we have been working on. TXA... | PMC10662860 |
5. Conclusion | blood loss, postoperative swelling, pain | BLOOD LOSS, COMPLICATIONS | Continuous cryotherapy combined with intra-articular injection of TXA provides short-term advantages in reducing blood loss, pain, postoperative swelling, p-LOS and increasing ROM and joint function in the early postoperative period after TKA without increasing any severe complications. | PMC10662860 |
Abbreviation: | knee arthroplasty | blood loss volumedeep venous thrombosishemoglobinhidden blood lossHospital for Special Surgerynormal salinepostoperative drainage volumepostoperative length of staypostoperative dayrange of motionsurgical site infectiontotal blood losstotal knee arthroplastytranexamic acidvisual analogue scaleXH and FL contributed equa... | PMC10662860 | |
References | PMC10662860 | |||
Objectives: | disability, Low back pain | CHRONIC LOW BACK PAIN | Low back pain is the leading cause of years lived with disability with a large impact on quality of life and resistance to a broad array of current treatments. This study aimed to investigate the effect of a novel self-administered behavioral therapy-based virtual reality (VR) application on the quality of life of pati... | PMC10205123 |
Methods: | depression, anxiety, pain | ADVERSE EVENTS | A pilot randomized controlled trial was conducted in adults with nonspecific CLBP with moderate to severe pain, waiting for treatment in a teaching hospital-based pain clinic. The intervention group used a self-administered behavioral therapy-based VR application for at least 10 minutes daily for 4 weeks. The control g... | PMC10205123 |
Results: | pain | Forty-one patients were included. One patient withdrew due to personal reasons. No significant treatment effect was found for the short form-12 physical score (mean difference: 2.6 points; 95% CI: −5.60 to 0.48) and mental score (−1.75; −6.04 to 2.53) at 4 weeks. There was a significant treatment effect for daily “wors... | PMC10205123 | |
Discussion: | pain | Four weeks of self-administered VR for CLBP does not improve quality of life, however, it may positively affect daily pain experience. | PMC10205123 | |
Key Words: | PMC10205123 | |||
INTRODUCTION | pain, disability, anxiety, Low back pain | DISORDERS | Low back pain is the leading cause of years lived with disability, accounting for over 10% of total years lived with disability.Treatment for CLBP consists mainly of physiotherapy and analgesics, in particular nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids.The use of a behavioral therapy-based virtual realit... | PMC10205123 |
METHODS | PMC10205123 | |||
Design | coronavirus disease | This was a pilot open-label randomized controlled trial conducted during the coronavirus disease (COVID) pandemic between January 2020 and January 2021 at Rijnstate Hospital, Arnhem, the Netherlands. The results of the qualitative part of this study have been reported earlier. | PMC10205123 | |
Participants | delirium, anxiety, epilepsy, Meticillin-resistant Staphylococcus aureus, dementia, pain, hearing/visual impairment, depression, Chronic pain | RECRUITMENT, EPILEPSY | The study population comprised patients of 18 years and older with nonspecific CLBP reporting an average pain score of 4 and higher on an 11-point Likert scale in the week preceding enrollment. Chronic pain was defined as pain lasting for at least 3 months. Other inclusion criteria were: (1) the patient has an estimate... | PMC10205123 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.